Peter Hunt, CROI 2022: Advances in HIV Cure with Clinical Perspectives
Despite antiretroviral treatment options becoming widely available, many patients living with HIV still do not have access to treatment. Prof. Peter Hunt (University of California San Francisco, San Francisco, CA, USA) discusses the reasoning behind the need for a HIV cure, comorbidities in an ageing population, therapeutic targets and clinical strategies that are currently under investigation for a HIV cure and the impact a cure may have on this patient population.
The presentation entitled: ‘Advances in HIV Cure with Clinical Perspectives’ (Abstract #479) was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- Despite numerous ART options, why is it important to develop a cure for HIV? (0:15)
- What therapeutic targets and clinical strategies are currently under investigation for a HIV cure? (2:36)
- If a HIV cure can be developed, what impact may it have on patients and society at large? (7:29)
Disclosures: Peter Hunt consults for Viiv Healthcare and Biotron; receives grant support from Gilead; and receives honoraria from Gilead and Viiv Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!